Open-Label and Single-Arm Study of MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adults

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 187 participants.

Also called NCT02610868

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 187 participants (enrolled count) (from the registry)
Sponsor
Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLC (from the registry)
Registry
  • NCT NCT02610868
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Belarus, Ukraine (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02610868. Allocation not applicable; no masking; primary purpose treatment. Start 2015-10 (registry gives no type); primary completion 2017-06 (actual). Results posted on 2019-11-04.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Open-Label and Single-Arm Study of MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adults
Acronym
OPTIMYST
Condition
Sialorrhea
Intervention (Drug)
MYOBLOC
Lead sponsor
Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLC (class: industry)

Record details

Record id
cardio:ct-nct02610868
Content hash
6bee95c493b50cc5a6714c1765ce3ac7e4b57bd09c2c2aaf94f555ae2dcdc558